Trials of probiotics in neonates showed a reduction in the relative risk for NEC [66–68] that may be due to the release of inhibitors of tumor necrosis factor-alpha (TNF-α) and NF-κB from the probiotic bacteria [69, 70]. This evidence concerns the gene NFKB1 and necrotizing enterocolitis.